PMID- 33305293
OWN - NLM
STAT- MEDLINE
DCOM- 20220414
LR  - 20231010
IS  - 2662-1347 (Electronic)
IS  - 2662-1347 (Linking)
VI  - 1
IP  - 2
DP  - 2020 Feb
TI  - Molecular analysis of primary melanoma T cells identifies patients at risk for 
      metastatic recurrence.
PG  - 197-209
LID - 10.1038/s43018-019-0019-5 [doi]
AB  - Primary melanomas >1 mm thickness are potentially curable by resection, but can 
      recur metastatically. We assessed the prognostic value of T cell fraction (TCFr) 
      and repertoire T cell clonality, measured by high-throughput-sequencing of the T 
      cell receptor beta chain (TRB) in T2-T4 primary melanomas (n=199). TCFr 
      accurately predicted progression-free survival (PFS) and was independent of 
      thickness, ulceration, mitotic rate, or age. TCFr was second only to tumor 
      thickness in its predictive value, using a gradient boosted model. For accurate 
      PFS prediction, adding TCFr to tumor thickness was superior to adding any other 
      histopathological variable. Furthermore, a TCFr >20% was protective regardless of 
      tumor ulceration status, mitotic rate or presence of nodal disease. TCFr is a 
      quantitative molecular assessment that predicts metastatic recurrence in primary 
      melanoma patients whose disease has been resected surgically. This study suggests 
      that a successful T cell-mediated antitumor response can be present in primary 
      melanomas.
FAU - Pruessmann, Wiebke
AU  - Pruessmann W
AD  - Department of Dermatology and Harvard Medical School, Brigham and Women's 
      Hospital, Boston, MA, USA.
AD  - Department of Dermatology, University of Luebeck, Luebeck, Germany.
FAU - Rytlewski, Julie
AU  - Rytlewski J
AUID- ORCID: 0000-0001-5244-6790
AD  - Adaptive Biotechnologies, Seattle, WA, USA.
FAU - Wilmott, James
AU  - Wilmott J
AUID- ORCID: 0000-0002-6750-5244
AD  - Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, 
      Australia.
FAU - Mihm, Martin C Jr
AU  - Mihm MC Jr
AD  - Department of Dermatology and Harvard Medical School, Brigham and Women's 
      Hospital, Boston, MA, USA.
FAU - Attrill, Grace H
AU  - Attrill GH
AD  - Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, 
      Australia.
FAU - Dyring-Andersen, Beatrice
AU  - Dyring-Andersen B
AD  - Department of Dermatology and Harvard Medical School, Brigham and Women's 
      Hospital, Boston, MA, USA.
AD  - Novo Nordisk Foundation Centre for Protein Research, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Fields, Paul
AU  - Fields P
AUID- ORCID: 0000-0002-9608-6464
AD  - Adaptive Biotechnologies, Seattle, WA, USA.
FAU - Zhan, Qian
AU  - Zhan Q
AD  - Department of Dermatology and Harvard Medical School, Brigham and Women's 
      Hospital, Boston, MA, USA.
FAU - Colebatch, Andrew J
AU  - Colebatch AJ
AD  - Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, 
      Australia.
AD  - Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, 
      Camperdown, New South Wales, Australia.
FAU - Ferguson, Peter M
AU  - Ferguson PM
AD  - Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, 
      Australia.
AD  - Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, 
      Camperdown, New South Wales, Australia.
FAU - Thompson, John F
AU  - Thompson JF
AUID- ORCID: 0000-0002-2816-2496
AD  - Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, 
      Australia.
AD  - Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, 
      Camperdown, New South Wales, Australia.
FAU - Kallenbach, Klaus
AU  - Kallenbach K
AD  - Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark.
FAU - Yusko, Erik
AU  - Yusko E
AD  - Adaptive Biotechnologies, Seattle, WA, USA.
FAU - Clark, Rachael A
AU  - Clark RA
AD  - Department of Dermatology and Harvard Medical School, Brigham and Women's 
      Hospital, Boston, MA, USA.
FAU - Robins, Harlan
AU  - Robins H
AD  - Adaptive Biotechnologies, Seattle, WA, USA.
AD  - Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
FAU - Scolyer, Richard A
AU  - Scolyer RA
AUID- ORCID: 0000-0002-8991-0013
AD  - Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, 
      Australia.
AD  - Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, 
      Camperdown, New South Wales, Australia.
FAU - Kupper, Thomas S
AU  - Kupper TS
AUID- ORCID: 0000-0002-4229-2916
AD  - Department of Dermatology and Harvard Medical School, Brigham and Women's 
      Hospital, Boston, MA, USA. tkupper@bwh.harvard.edu.
LA  - eng
GR  - P30 CA006516/CA/NCI NIH HHS/United States
GR  - R01 AI127654/AI/NIAID NIH HHS/United States
GR  - R01 AR065807/AR/NIAMS NIH HHS/United States
GR  - R01 CA203721/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200120
PL  - England
TA  - Nat Cancer
JT  - Nature cancer
JID - 101761119
EIN - Nat Cancer. 2020 Apr;1(4):470. PMID: 35121971
MH  - Humans
MH  - *Melanoma/genetics
MH  - T-Lymphocytes/pathology
PMC - PMC7725220
MID - NIHMS1638625
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
PMCR- 2020/12/09
CRDT- 2020/12/11 06:06
PHST- 2020/12/11 06:06 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
PHST- 2020/12/09 00:00 [pmc-release]
AID - 10.1038/s43018-019-0019-5 [pii]
AID - 10.1038/s43018-019-0019-5 [doi]
PST - ppublish
SO  - Nat Cancer. 2020 Feb;1(2):197-209. doi: 10.1038/s43018-019-0019-5. Epub 2020 Jan 
      20.